Address insulin resistance when routine screening finds prediabetes or diabetes, or when your age and health risks indicate that glucose testing is due. Insulin resistance—when the body responds poorly to insulin—should be managed as a metabolic and cardiovascular risk, not as a proven dementia treatment. The distinction matters because diabetes is linked to dementia, while evidence connecting brain insulin resistance directly to Alzheimer's disease remains inconclusive. A dementia prevention plan should target confirmed risks without promising that glucose treatment will prevent cognitive decline.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the dementia evidence show?
- Why not treat insulin resistance as an Alzheimer's therapy?
- When should you ask for glucose testing?
- What action is supported for prediabetes?
- When might medication be considered?
What does the dementia evidence show?
The 2024 Lancet Commission identifies diabetes—not insulin resistance alone—as one of 14 potentially modifiable dementia risk factors. It estimates that diabetes accounts for about 2% of dementia cases globally, while emphasizing prevention across many risks in its dementia prevention report. A pooled analysis of 14 cohort studies included more than 2.3 million people with type 2 diabetes.
Diabetes was associated with about a 60% higher risk of any dementia, and risk increased with longer or more severe disease. That association does not prove that lowering glucose prevents dementia. It does, however, support identifying and treating diabetes as one part of protecting long-term vascular and brain health.
Why not treat insulin resistance as an Alzheimer's therapy?
"Brain insulin resistance" is a proposed problem involving impaired insulin activity in the brain. It is not interchangeable with a clinical diagnosis of prediabetes or type 2 diabetes. A 2024 systematic review found the relationship between brain insulin resistance and Alzheimer's disease inconclusive in the available research.
Insulin-resistance treatment therefore cannot be presented as an established dementia-prevention therapy. Be cautious with programs that promise to prevent Alzheimer's disease by "reversing insulin resistance" alone. A metabolic intervention may reduce diabetes risk while still having no proven effect on whether an individual develops dementia.
When should you ask for glucose testing?
Do not wait for memory problems before addressing metabolic risk. The USPSTF recommends screening adults ages 35–70 who have overweight or obesity, even when they have no symptoms, and referring those with prediabetes to an effective prevention program. The American Diabetes Association recommends testing all adults no later than age 35.
It also recommends earlier testing for people with overweight or obesity plus additional risks listed in its 2026 Standards of Care. Those additional risks include: If testing confirms prediabetes or diabetes, discuss the result as part of both a cardiovascular and brain-health plan. An unconfirmed "insulin resistance" label should not replace standard glucose testing.
- High blood pressure or cardiovascular disease
- Physical inactivity
- Polycystic ovary syndrome
- Fatty liver disease
- Acanthosis nigricans, which causes darkened, thickened skin
What action is supported for prediabetes?
For adults at high risk with elevated glucose, structured lifestyle change has strong evidence for preventing or delaying type 2 diabetes. In the Diabetes Prevention Program, a lifestyle intervention targeting at least 7% weight loss and 150 minutes of weekly activity reduced diabetes incidence by 58% over 2.8 years; metformin reduced it by 31% in the clinical trial.
The trial did not establish that either approach prevents dementia. Its practical value in a dementia prevention plan is reducing progression toward diabetes, a recognized dementia risk factor. A useful appointment checklist is:.
- Review whether glucose screening is due.
- Ask what a prediabetes or diabetes result means for you.
- Discuss a realistic activity and weight-management plan when appropriate.
- Review blood pressure, lipids, smoking, and other cardiovascular risks.
- Set a follow-up plan rather than relying on a single test or commercial insulin-resistance score.
When might medication be considered?
Metformin is not recommended solely because someone fears dementia. The ADA says clinicians should consider it mainly for adults at particularly high risk of diabetes, especially those ages 25–59 with a body mass index of at least 35, fasting glucose of at least 110 mg/dL, A1C of at least 6.0%, or previous gestational diabetes. Medication decisions should follow confirmed metabolic findings and an individual clinical assessment.
Do not start glucose-lowering treatment based only on family history of dementia, memory concerns, or claims about brain insulin resistance. A broader plan also addresses obesity, blood pressure, lipids, physical activity, smoking, hearing, and social factors. The concrete next step is to check whether you meet screening criteria and review any abnormal result with a clinician.
